Salarius Pharmaceuticals, Inc. filed an 8-K to report a second amendment to its merger agreement with Decoy Therapeutics on June 10, 2025, adjusting ownership percentages to 7.6% for Salarius and 92.4% for Decoy due to a significant drop in stock valuation.